With optimism and energy pervading the Chinese healthcare landscape, actors of all stripes see new potential and opportunities on the horizon. The heterogeneity of the Chinese market, with its 31 province-level entities offering a variety of market characteristics and needs;…
Building on the topics covered in our March 2019 report, this latest edition of Healthcare & Life Sciences Review Spain takes a closer look at the broader Spanish life sciences value chain. With the Iberian nation enjoying an economic rebound, pharmaceutical…
Now enjoying a period of relative political stability and with a swathe of economic reforms in the pipeline, Egypt is once more becoming one of the most favourable investment destinations in its region. Nowhere is this trend more apparent than in healthcare. With the launch…
Following on from our March 2019 report, this latest issue of Healthcare & Life Sciences Review France takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation. A reform-minded and…
One of the indisputable economic success stories of the last half century, South Korea now stands as the world’s 11th largest economy, with a reputation for industrial excellence and innovation. As the Korean state shifts its focus towards healthcare and the life sciences…
China is the country it is impossible to ignore and now accounts for a significant share of revenues for most major multinational pharmaceutical companies. Further, any firm sincerely committed to bringing treatments to the greatest number of patients has to be active in…
France – under the business-minded administration of President Emmanuel Macron – has been rapidly climbing investor priority rankings in recent years. This report examines the potential impact of a swathe of ambitious recently-approved reforms and a new mood of…
Having largely recovered from the impact of the global financial crisis and with several impressive fundamentals in place, Spain once again stands as one of Europe’s premier healthcare and life science investment destinations. These fundamentals include a revamped market…
Turkey – home to an 80 million-strong population, a substantial pharmaceuticals market and a universal healthcare system that is the envy of its neighbours – stands as one of the most promising healthcare and life science investment destinations in its region. Topics…
Topics covered in this report – which features the exclusive insights of government ministers, the heads of local pharma champions as well as multinational affiliate leaders – include the potential impact of Algeria’s sweeping new healthcare law, the establishment…
Through exclusive interviews with the Malaysian Minister of Health as well as the head of the country’s regulatory body – the NPRA – this report examines emerging trends in Malaysian healthcare, with Prime Minister Matahir Mohamad spearheading a bold health policy…
Despite its small population size, Hong Kong has long held a strategic interest for the healthcare and life sciences industries, whether as a testbed for innovative products and service delivery models as a result of its efficient regulatory approval system or as an…